Clinical Trial Goal
To find out if the combination of belantamab mafodotin and lenalidomide is safe and works well to treat multiple myeloma after autologous BMT
You may be able to join this trial if you:
- Are 18 years or older
- Have multiple myeloma and have had little to no treatment
- Have had an autologous BMT in the last 2 - 6 months
- Do not have one of the following:
- Plasma cell leukemia
- Smoldering multiple myeloma
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Belantamab mafodotin is an antibody-drug conjugate, or combination, that combines belantamab with a chemotherapy (chemo) drug called mafodotin and targets BCMA on certain cells.
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get:
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get:
- Belantamab mafodotin – Given as intravenous (IV) infusions. Up to 1 time every other month
- Lenalidomide – A pill that you take by mouth 1 time each day. You get 1 week off after every 3 weeks of treatment
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat multiple myeloma after autologous BMT is new and unproven.
Locations
MD Anderson Cancer CenterRECRUITING
Houston, Texas
Qaiser Bashir, MD, 713-794-4422, qbashir@mdanderson.org
Sponsors
lead: M.D. Anderson Cancer Center
